Author

Hyejung Lee

Institution: Daewoong Pharmaceutical (South Korea)

Observed institution: Daewoong Pharmaceutical (South Korea)

ORCID: 0000-0002-2143-2852

Observed ORCID: 0000-0002-2143-2852

OpenAlex ID: A5038803933

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects

2023 · JungJin Oh, Eunsol Yang, et al. · Pharmaceutics · 10

Comparing the Efficacy and Safety of Fexuprazan and Lansoprazole for the Prevention of Nonsteroidal Anti-inflammatory Drug-Induced Peptic Ulcer

2025 · Seokchan Hong, Ji Hyeon Ju, et al. · Gut and Liver · 7

Pharmacokinetic interactions between fexuprazan, a potassium‐competitive acid blocker, and nonsteroidal anti‐inflammatory drugs in healthy males

2024 · Heejae Won, Eunwoo Kim, et al. · Clinical and Translational Science · 5

A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State

2023 · Wonsuk Shin, A-Young Yang, et al. · Pharmaceuticals · 5

Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation

2023 · A-Young Yang, Hyounggyoon Yoo, et al. · Translational and Clinical Pharmacology · 5

Works count: 5

Citation count: 32

H-index: 5

I10-index: 1